FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.

Authors

• William Kelly

Publication/Presentation Date

5-2019

Volume

37

Issue

15

Published In/Presented At

DOI: 10.1200/JCO.2019.37.15_suppl.4511

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article